ÂBÂngela Maria Bagattini

Ângela Maria Bagattini

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ângela Maria Bagattini has a total of 82 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Health resource use and epidemiologic profile of herpes zoster outpatients aged 50 years or older: a modified Delphi consensus panel in Brazil

    by Ângela Maria Bagattini, Michelle Quarti Machado da Rosa, Jorge A. Gomez, Jamile Ballivian, Agustín Casarini, Ariel Bardach, Cristiana Maria Toscano


  • Open Access

    Modelagem da COVID-19 no Brasil e a interação entre academia e gestores durante a pandemia

    by Michelle Quarti Machado da Rosa, Ângela Maria Bagattini, Isabella Inês Rodrigues Rosa, Gabriel Berg de Almeida, Lorena Mendes Simon, Suzi Alves Camey, Cristiana Maria Toscano

    Resumo A modelagem desempenhou papel significativo no apoio a políticas públicas durante a pandemia de COVID-19, e a tomada de decisão enfrentou um contexto de evidências limitadas. Este é um estudo transversal que incluiu e caracterizou instituições e grupos de pesquisadores que trabalharam com modelagem de COVID-19 e apoiaram a tomada de decisão. Utilizamos duas estratégias para identificação: 1) revisão de escopo e 2) amostragem de grupos através de referência em cadeia. Foram identificados um total de 100 estudos e 30 instituições. Dos 40 pesquisadores que relataram interação com gestores de saúde, 20 foram entrevistados, sendo programadores, matemáticos, médicos, epidemiologistas, estatísticos e físicos. Em relação às parcerias institucionais, 14 pesquisadores relataram ter colaborado em parcerias nacionais e/ou internacionais. Apenas alguns (5) relataram algum tipo de formalização de colaboração entre o grupo e a gestão. Observamos uma lacuna na demanda de modelagem e na comunicação para apoiar a gestão durante a pandemia de COVID-19. Repensar o processo de formulação e implementação de políticas públicas em emergências de saúde pode promover sistemas de saúde sólidos e melhores respostas a pandemias.

  • Open Access

    Judicialização da saúde: Um estudo sobre os custos com medicamentos para a Atrofia Muscular Espinhal (AME) na perspectiva do SUS

    by Ligia Oliveira Almeida Mendes, Angela Maria Bagattini

    Introdução: A Atrofia Muscular Espinhal (AME) é uma doença neuromuscular rara e hereditária, que causa fraqueza muscular e atrofia devido a mutações no gene SMN1, resultando na deficiência da proteína SMN, essencial para a sobrevivência dos neurônios motores. A gravidade da doença varia, com o tipo 1 sendo o mais severo e os tipos 2, 3 e 4 apresentando sintomas mais leves. Avanços recentes trouxeram tratamentos inovadores como Nusinersena, Risdiplam e Onasemnogene Abeparvovec, que melhoram a função motora e retardam a progressão da doença. No entanto, a acessibilidade a esses tratamentos enfrenta desafios devido aos altos custos, exigindo estratégias eficazes de financiamento e distribuição. No Brasil, a gestão da AME é ainda mais complexa devido à judicialização da saúde, onde decisões judiciais determinam o acesso e o financiamento desses medicamentos, pressionando os recursos do SUS e afetando a previsibilidade orçamentária. Este trabalho analisa as modalidades de aquisição desses medicamentos pelo Ministério da Saúde, oferecendo reflexões para políticas públicas que garantir a sustentabilidade econômica no acesso aos tratamentos. Objetivo: O estudo analisou o custo dos medicamentos disponíveis no SUS para o tratamento da AME, considerando as diferentes formas de aquisição no período de 2019 a 2022, comparando o custo para o SUS entre os medicamentos adquiridos pelo Ministério da Saúde tanto por via administrativa quanto por via judicial. Material e Método: Foi realizado um estudo quantitativo, retrospectivo, com abordagem descritiva e analítica sobre o custo para o Ministério da Saúde na aquisição de medicamentos para AME disponíveis no SUS. Resultados: Com base nas informações fornecidas, foram identificadas diferenças nos valores médios unitários das aquisições de cada medicamento por diferentes vias. Para o medicamento Nusinersena, por exemplo, em 2019, se todas as unidades adquiridas via DJUD tivessem o mesmo valor médio unitário das aquisições via CEAF, teria havido uma economia de aproximadamente R$ 53.782,96 por unidade adquirida, representando uma economia total de cerca de R$ 50.244.000,00 para o SUS naquele ano. Já para o Risdiplam, enquanto a aquisição via CEAF apresentou um valor médio unitário de R$21.370,00, às vias judiciais registraram valores médios unitários mais altos, chegando a R$76.315,00. Com base nesses dados, estima-se que se todas as aquisições fossem realizadas via CEAF, o SUS poderia economizar cerca de R$30.566.440,00, o que representaria aproximadamente 60% de economia em relação àsvias judiciais. Conclusões: O trabalho destaca a importância de políticas de saúde que equilibram o acesso a tratamentos coma sustentabilidade dos sistemas de saúde. A centralização das compras pelo CEAF mostrou-se eficaz na redução de custos e nagestão eficiente dos recursos públicos. Para o futuro, é crucial fortalecer a colaboração entre os diversos atores envolvidos visandopolíticas que garantam acesso equitativo e sustentável a medicamentos de alto custo.

  • Open Access

    Dynamic transmission modeling of COVID-19 to support decision-making in Brazil: A scoping review in the pre-vaccine era

    by Gabriel Berg de Almeida, Lorena Mendes Simon, Ângela Maria Bagattini, Michelle Quarti Machado da Rosa, Marcelo Eduardo Borges, José Alexandre Felizola Diniz Filho, Ricardo de Souza Kuchenbecker, Roberto André Kraenkel, Cláudia Pio Ferreira, Suzi Alves Camey, et al.

    Brazil was one of the countries most affected during the first year of the COVID-19 pandemic, in a pre-vaccine era, and mathematical and statistical models were used in decision-making and public policies to mitigate and suppress SARS-CoV-2 dispersion. In this article, we intend to overview the modeling for COVID-19 in Brazil, focusing on the first 18 months of the pandemic. We conducted a scoping review and searched for studies on infectious disease modeling methods in peer-reviewed journals and gray literature, published between January 01, 2020, and June 2, 2021, reporting real-world or scenario-based COVID-19 modeling for Brazil. We included 81 studies, most corresponding to published articles produced in Brazilian institutions. The models were dynamic and deterministic in the majority. The predominant model type was compartmental, but other models were also found. The main modeling objectives were to analyze epidemiological scenarios (testing interventions’ effectiveness) and to project short and long-term predictions, while few articles performed economic impact analysis. Estimations of the R0 and transmission rates or projections regarding the course of the epidemic figured as major, especially at the beginning of the crisis. However, several other outputs were forecasted, such as the isolation/quarantine effect on transmission, hospital facilities required, secondary cases caused by infected children, and the economic effects of the pandemic. This study reveals numerous articles with shared objectives and similar methods and data sources. We observed a deficiency in addressing social inequities in the Brazilian context within the utilized models, which may also be expected in several low- and middle-income countries with significant social disparities. We conclude that the models were of great relevance in the pandemic scenario of COVID-19. Nevertheless, efforts could be better planned and executed with improved institutional organization, dialogue among research groups, increased interaction between modelers and epidemiologists, and establishment of a sustainable cooperation network.


  • PP25 Brazilian Collaborative Network For COVID-19 Modeling: Successful Experience Of Using Real-Time Science To Support Evidence-Based Decision-Making

    by Ângela Maria Bagattini, Michelle Rosa, Lorena Mendes Simon, Gabriel Berg de Almeida, Leonardo Souto Ferreira, Marcelo Eduardo Borges, Roberto André Kraenkel, Renato Mendes Coutinho, José Alexandre Felizola Diniz Filho, Suzi Alves Camey, et al.

    Introduction Modeling is important for guiding policy during epidemics. The objective of this work was to describe the experience of structuring a multidisciplinary collaborative network in Brazil for modeling coronavirus disease 2019 (COVID-19) to support decision-making throughout the pandemic. Methods Responding to a national call in June 2020 for proposals on COVID-19 mitigation projects, we established a team of investigators from public universities located in various regions throughout Brazil. The team’s main objective was to model severe acute respiratory syndrome coronavirus 2 transmission dynamics in various demographic and epidemiologic settings in Brazil using different types of models and mitigation interventions. The modeling results aimed to provide information to support policy making. This descriptive study outlines the processes, products, challenges, and lessons learned from this innovative experience. Results The network included 18 researchers (epidemiologists, infectious diseases experts, statisticians, and modelers) from various backgrounds, including ecology, geography, physics, and mathematics. The criteria for joining the network were having a communication channel with public health decision-makers and being involved in generating evidence for public policy. During a 24-month period, the following sub-projects were established: (i) development of a susceptible-exposed-infected-recovered-like, individual-based meta-population and Markov chain model; (ii) projection of COVID-19 transmission and impact over time with respect to cases, hospitalizations, and deaths; (iii) assessment of the impact of non-pharmacological interventions for COVID-19; (iv) evaluation of the impact of reopening schools; and (v) determining optimal strategies for COVID-19 vaccination. In addition, we mapped existing COVID-19 modeling groups nationwide and conducted a systematic review of relevant published research literature from Brazil. Conclusions Infectious disease modeling for guiding public health policy requires interaction between epidemiologists, public health specialists, and modelers. Communicating modeling results in a non-academic format is an additional challenge, so close interaction with policy makers is essential to ensure that the information is useful. Establishing a network of modeling groups will be useful for future disease outbreaks.

  • Open Access

    Systematic review of immunogenicity and duration of immunity of currently licensed pertussis wP vaccines in children

    by Angela M. Bagattini, Michelle M. Quarti, Martha S. Martinez-Silveira, Gabriela Policena, Lara E. Coelho, Paula M. Luz, Louise B. Russell, Cristiana M. Toscano

    Background: Currently recommended whole cell pertussis (wP) vaccination schedule for children includes a 3-dose primary schedule, and at least one booster dose. When estimating the impact of additional strategies to reduce pertussis burden through modelling, duration of immunity conferred by childhood immunization is among the parameters models are most sensitive to. We aim to assess the duration of immunity of currently available wP vaccines in children and the additional protection conferred by booster doses. Methods: We conducted a systematic review of published studies of current commercially available vaccines indexed in Medline, Embase, Web of Science, Lilacs, SciELO and Central until September 2021. We included clinical trials, observational longitudinal, and cross-sectional studies. Citation screening, data extraction, and risk of bias and methodological quality assessment were done in duplicate by independent reviewers, following the study protocol registered in PROSPERO. Studies were included if they reported primary data on the protection, immunity, or duration of immunity conferred by ≥3 doses of wP vaccine in healthy children, without restriction to time or location of the study. Outcomes included clinical events or serological evidence of protection. Results: We included 12 studies conducted from 2007-2020 with heterogeneous methodological quality. Studies report on 5 of the 18 currently available wP vaccines in use. After primary immunization, geometric mean concentration (GMC) of anti-pertussis toxin ranged from 9.1 EU/mL (95% confidence intervals [CI]: 8.1-10.2) to 50.9 (95%CI: 45.9-56.4). Prior to the 1st booster, GMC titers were low ranging from 4.7 to 10 EU/mL, and after the 1st booster averaged around 42 EU/mL. Conclusions: The limited available evidence on immunogenicity of currently available wP vaccines reinforces the need for booster doses and suggests that the duration of wP immunity is short, probably <5 years. This is important information for vaccination policy makers, investigators and modelers. PROSPERO registration: CRD42018107309


  • Open Access

    Automation of a tertiary hospital pharmacy drug dispensing system in a lower-middle-income country: A case study and preliminary results

    by Ângela Maria Bagattini, José Luiz Alvim Borges, Rachel Riera, Débora Cecília Mantovani Faustino de Carvalho


  • Open Access

    Micro-Costing of a Remotely Operated Referral Management System to Secondary Care in the Unified Health System in Brazil

    by Daniela Vianna Pachito, Ana Paula Beck da Silva Etges, Patrícia Roberta Berithe Pedrosa de Oliveira, Josué Basso, Ângela Maria Bagattini, Rachel Riera, Luana Gonçalves Gehres, Érica de Brito Mallmann, Átila Szczecinski Rodrigues, Sabrina Dalbosco Gadenz

    Referral of cases from primary to secondary care in the Brazilian public healthcare system is one of the most important issues to be tackled. Telehealth strategies have been shown effective in avoiding unnecessary referrals. The objective of this study was to estimate cost per referred case by a remotely operated referral management system to further inform the decision making on the topic. Analysis of cost by applying time-driven activity-based costing. Cost analyses included comparisons between medical specialties, localities for which referrals were being conducted, and periods of time. Cost per referred case across localities ranged from R$ 5.70 to R$ 8.29. Cost per referred case across medical specialties ranged from R$ 1.85 to R$ 8.56. Strategies to optimize the management of referral cases to specialized care in public healthcare systems are still needed. Telehealth strategies may be advantageous, with cost estimates across localities ranging from R$ 5.70 to R$ 8.29, with additional observed variability related to the type of medical specialty.


  • Efficacy and safety of therapeutic use of cannabis derivatives and their synthetic analogs: Overview of systematic reviews

    by Rachel Riera, Rafael Leite Pacheco, Ângela Maria Bagattini, Ana Luiza Cabrera Martimbianco

    The debate on the use of cannabinoids for therapeutic purposes is constantly on the rise. This overview aimed to map the evidence on the therapeutic effects of cannabis derivatives and their synthetic analogs. Systematic reviews (SRs) of randomized trials were identified through a comprehensive search in several databases, and their methodological quality were evaluated with AMSTAR‐2. The results for main outcomes are presented, prioritizing those from updated and better quality SRs. Finally, 68 SRs, addressing 37 different health conditions, were included. The methodological quality was high for eight SRs. The evidence certainty (GRADE) for the effects of cannabinoids is not high for any of the outcomes identified. Evidence certainty was moderate for the following: (a) cannabidiol appears to be beneficial for quality of life but increases the risk of adverse events in ulcerative colitis; (b) cannabinoids in general appear to have no clinically important benefit for chronic non‐oncologic pain, spasticity‐related pain in multiple sclerosis, or for acute post‐operative pain; (c) cannabinoids in general appear to have a benefit in reducing chemotherapy‐related nausea and vomiting. For all other outcomes from remaining comparisons, the evidence certainty was low, very low, or not evaluated, which prevents recommendations for or against their routine use.


  • Open Access

    Modelling optimal vaccination strategies against Covid-19 in a context of Gamma variant predominance in Brazil

    by Leonardo Souto Ferreira, Gabriel Berg de Almeida, Marcelo Eduardo Borges, Lorena Mendes Simon, Silas Poloni, Ângela Maria Bagattini, Michelle Quarti Machado da Rosa, José Alexandre Felizola Diniz Filho, Ricardo de Souza Kuchenbecker, Suzi Alves Camey, et al.

    Summary: Brazil experienced moments of collapse in its health system throughout 2021, driven by a timid initial vaccination strategy against Covid-19, combined with the emergence of variants of interest (VOC). Mathematical modelling has been used to subsidize decision-makers in public health planning. Considering the vaccine products available, effectiveness estimates, the emergence of Gamma as the predominant VOC circulating in 2021, and national estimated doses available for the next several months, we developed a Markov-chain mathematical modelling approach to evaluate optimal strategies for Covid-19 vaccination in Brazil in terms of Covid deaths averted. Our main findings are that in order to reach higher vaccination impact in Brazil, Covid-19 immunization strategies should include recovering vaccination coverage rates in high-risk groups reaching higher coverage; expanding vaccination to younger age groups should be considered only after ensuring at least 80% coverage in older age groups; reducing the interval between doses of AZD1222 from 12 to 8 weeks. We also demonstrate that the latter is only feasible if accompanied by an increase in vaccine supply of at least 50% in the next six month period.